863 Mitten Road Suite 104
Burlingame, CA 94010
Tel: (650) 443-3030
About Inflammatix, Inc.
Inflammatix, Inc. is a venture-backed diagnostics company bringing the power of precision medicine to the point- of-care. We are building novel diagnostic, prognostic, and predictive tests that combine rapid detection of human immune gene expression (mRNA) panels with advanced machine learning. These tests will be performed on our rapid point-of-care instrument currently under development. Our first tests, planned to be commercialized in 2021, will enable physicians to better diagnose acute infections and sepsis (including COVID-19).
Dr. Tim Sweeney, Inflammatix Co-Founder and CEO TEDx Palo Alto: 'The power of reading the immune system to better diagnose disease'
11 articles with Inflammatix, Inc.
Inflammatix , a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021.
3/17/2021Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Inflammatix , a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures.
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic That Predicts COVID-19 Severity Risk
New Data Shows Inflammatix Machine Learning-Based Approach of Reading Immune System is Superior to IL-6 and Other Measures in Predicting Patients at High Risk for Severe COVID-19 BURLINGAME, Calif.--( BUSINESS WIRE )-- Inflammatix , a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads
New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response.
Inflammatix, a molecular diagnostics company that is reimagining diagnostics, announced today that it has received the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.
Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.
Inflammatix to Present New Data at IDWeek 2018 Demonstrating Ability to Perform HostDx™ Fever Test to Rapidly Distinguish Bacterial from Viral Infections Across Multiple Laboratory Platforms
Novel data-driven test reads the immune system response to help diagnose acute infections
Dr. Liesenfeld, a veteran of the diagnostics industry, comes to the company from Roche Molecular Diagnostics, where he served as chief medical officer since 2012.